Giardia lamblia (G. intestinalis)

Giardia lamblia (intestinalis) causes giardiasis, a parasitic infestation that can manifest as latent parasitic carriage or in more pronounced forms, such as intestinal dysfunction. Giardiasis has been recorded on all five continents and in most countries worldwide. Infection rates vary from less than 1% to 50%. In many developing countries, where basic sanitary conditions are lacking, infection with Giardia in children by the age of 2 is almost universal. In contrast, in developed countries, the infection rate of G.lamblia is only 3–7%. The disease affects all age groups, but preschool-aged children are the most affected demographic.

The primary route of transmission for G.lamblia is fecal-oral. The parasite has a simple two-stage life cycle. After the host ingests cysts, they release trophozoites in the duodenum, which then attach to the mucosal lining of the small intestine.

Trophozoites exist only on the surface of the mucosa in the upper part of the small intestine. Therefore, Giardia mechanically blocks the mucosa and disrupts membrane digestion and the motor activity of the small intestine. Giardia impairs the absorption of fats, carbohydrates, vitamins C and B12, and leads to secondary bacterial infections. Symptoms of giardiasis can include diarrhea, fatigue, bloating, apathy, weight loss, decreased appetite, pallor, and muscle twitching. From the gastrointestinal tract perspective, giardiasis mainly manifests as enterocolitis with catarrhal symptoms.

Numerous findings indicate the role of the humoral immune response in the elimination of G.lamblia. As shown in an experimental human infection model, IgM antibody levels significantly increased on days 14-21 post-infection and gradually declined following therapy. In contrast, IgG antibody levels remained elevated after successful treatment. The dynamics of IgA levels were similar to those of IgM.

The diagnosis of giardiasis is based on clinical history, symptoms, and the presence of cysts in fecal samples or trophozoites in material obtained from the small intestine during duodenal aspiration or duodenal biopsy. Alternative methods include the detection of G.lamblia antigen in feces and the determination of specific antibodies against Giardia in the patient’s serum. Serological testing is considered a valuable adjunct in the diagnosis of giardiasis. In addition to aiding in diagnosis, it can be useful for assessing the patient’s immune response and for epidemiological studies.

Giardia lamblia (intestinalis) causes giardiasis, a parasitic infestation that can manifest as latent parasitic carriage or in more pronounced forms, such as intestinal dysfunction. Giardiasis has been recorded on all five continents and in most countries worldwide. Infection rates vary from less than 1% to 50%. In many developing countries, where basic sanitary conditions are lacking, infection with Giardia in children by the age of 2 is almost universal. In contrast, in developed countries, the infection rate of G.lamblia is only 3–7%. The disease affects all age groups, but preschool-aged children are the most affected demographic.

The primary route of transmission for G.lamblia is fecal-oral. The parasite has a simple two-stage life cycle. After the host ingests cysts, they release trophozoites in the duodenum, which then attach to the mucosal lining of the small intestine.

Trophozoites exist only on the surface of the mucosa in the upper part of the small intestine. Therefore, Giardia mechanically blocks the mucosa and disrupts membrane digestion and the motor activity of the small intestine. Giardia impairs the absorption of fats, carbohydrates, vitamins C and B12, and leads to secondary bacterial infections. Symptoms of giardiasis can include diarrhea, fatigue, bloating, apathy, weight loss, decreased appetite, pallor, and muscle twitching. From the gastrointestinal tract perspective, giardiasis mainly manifests as enterocolitis with catarrhal symptoms.

Numerous findings indicate the role of the humoral immune response in the elimination of G.lamblia. As shown in an experimental human infection model, IgM antibody levels significantly increased on days 14-21 post-infection and gradually declined following therapy. In contrast, IgG antibody levels remained elevated after successful treatment. The dynamics of IgA levels were similar to those of IgM.

The diagnosis of giardiasis is based on clinical history, symptoms, and the presence of cysts in fecal samples or trophozoites in material obtained from the small intestine during duodenal aspiration or duodenal biopsy. Alternative methods include the detection of G.lamblia antigen in feces and the determination of specific antibodies against Giardia in the patient’s serum. Serological testing is considered a valuable adjunct in the diagnosis of giardiasis. In addition to aiding in diagnosis, it can be useful for assessing the patient’s immune response and for epidemiological studies.